Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL25345242 | 0.91 | TSHR (0.50) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL11857403 | 0.86 | MAPT (0.55) | GLAMAPTGAATDP1MEN1 | |
| SCHEMBL1000014 | 0.84 | MMP2 (0.54) | MMP2CA12CA1CA2CA7 | |
| SCHEMBL570378 | 0.84 | CA12 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1502516 | 0.83 | PARP1 (0.41) | MMP2KDM4EMAPTGAATDP1 | |
| SCHEMBL1189236 | 0.81 | THRB (0.45) | MMP2KDM4EMAPTTDP1ALDH1A1 | |
| SCHEMBL19972022 | 0.81 | ALDH1A1 (0.45) | MMP2KDM4EMAPTCASP7GAA | |
| SCHEMBL18043789 | 0.79 | MMP2 (0.50) | MMP2CA12CA1CA2CA7 | |
| SCHEMBL1189541 | 0.76 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15520067 | 0.76 | HDAC8 (0.42) | CA2KDM4EGAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117659069-A | Synthesis method of 2-methyl-5- (4, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) quinoline | 南通敏言生物医药科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-115010671-B | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2023-10-10 | — | — | CN | claimed |
| CN-115010671-A | One-step synthesis method of 2-substituted quinazolinone | 江苏大学 | 2022-09-06 | — | — | CN | claimed |
| CN-106995438-B | A kind of substituted quinazoline -4- ketone compounds and preparation method thereof and medical usage | 中国科学院上海药物研究所 | 2019-09-20 | — | — | CN | claimed |
| CN-106995438-A | One class substituted quinazoline -4- ketone compounds and preparation method thereof and medical usage | 中国科学院上海药物研究所 | 2017-08-01 | — | — | CN | claimed |
| US-4673740-A | Preparation of substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | claimed |
| CN-122036604-A | Compound and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4695250-A1 | TETRACYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS | Aurigene Oncology Limited (IN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| CN-120058621-A | 2, 3-Dihydro quinazoline derivative containing substituted phenyl, preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-30 | — | — | CN | disclosed |
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2024-12-26 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| US-4673740-A | Preparation of substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
| US-4337270-A | ANTIALLERGENS; ANTIANAPHYLACTIC AGENTS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1982-06-29 | — | — | US | disclosed |
| US-4154745-A | Isobenzofuran route to anthracycloquinones | RESEARCH CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4116981-A | 5,12-EPOXY-NAPHTHACENE-6,11-DIONE DERIVATIVES | Tsay, Yuh-Geng (TW) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | MMP2 4262/4885CA12 4859/4885CA1 4239/4885 |
| US-20240425475-A1 | COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF | CRBN, CLN6, CDR2 | MMP2 3512/4885CA12 1261/4885CA1 292/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | MMP2 4362/4885CA12 4020/4885CA1 2445/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MMP2 3159/4885CA12 4736/4885CA1 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.